Corcept Inks $14M Investor Deal Over Off-Label Drug Sales
Corcept Therapeutics Inc. has reached a $14 million settlement to end securities fraud litigation related to ifs mifepristone drug Korlym in a deal that includes a potential 25% cut for the...To view the full article, register now.
Already a subscriber? Click here to view full article